Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CND Life Sciences Raises $13.5M in Series A | Contract Pharma
Breaking News

CND Life Sciences Raises $13.5M in Series A

Will fund continued neurodiagnostics growth and innovation.

CND Life Sciences Inc. has raised $13.5 million in its Series A equity financing round, with $8.6 million in its most recent Series A3 offering. The company’s strong growth has been fueled by its Syn-One Test that uses skin biopsy tissue to detect and quantify the abnormal form of the alpha-synuclein protein, a known pathological hallmark of Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy and other related disorders.

“This is a defining time for the neurodegeneration field,” said Richard J. Morello, CND’s CEO. “CND uses proven technology to help clinicians diagnose diseases like Parkinson’s earlier and more precisely than ever before, while collaborating with biopharmaceutical companies to improve the chances for successful clinical trials for novel therapies. We are grateful for the significant support of our mission by many dedicated investors.”

CND’s latest Series A3 round included funding from existing investor groups Cambrian Capital Partners, Tanis Ventures, Lupo Labs, Top Corner Capital, HonorHealth, Triana, Gold Bench Capital and BlueStone Ventures and from new investors Labcorp, a global leader of innovative and comprehensive laboratory services, MBX Capital and Vilas Ventures.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters